These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

309 related items for PubMed ID: 38701084

  • 21. Pharmaceutical cost dynamics for the treatment of rifampicin-resistant tuberculosis in children and adolescents in South Africa, India, and the Philippines.
    Wilkinson T, Garcia-Prats AJ, Sachs T, Paradkar M, Suryavanshi N, Kinikar A, Frias MV, Sinanovic E, Hesseling AC, Seddon JA, Palmer M.
    PLoS One; 2024; 19(7):e0305930. PubMed ID: 39042708
    [Abstract] [Full Text] [Related]

  • 22. Savings from the introduction of BPaL and BPaLM regimens at the country level.
    Auer C, Gupta A, Malbacius C, Ghafoor A, Kock Y, Medvedieva O, Hanlon P, Steinmann P, Juneja S.
    IJTLD Open; 2024 Jul; 1(7):314-319. PubMed ID: 39035434
    [Abstract] [Full Text] [Related]

  • 23. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
    Tweed CD, Dawson R, Burger DA, Conradie A, Crook AM, Mendel CM, Conradie F, Diacon AH, Ntinginya NE, Everitt DE, Haraka F, Li M, van Niekerk CH, Okwera A, Rassool MS, Reither K, Sebe MA, Staples S, Variava E, Spigelman M.
    Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
    [Abstract] [Full Text] [Related]

  • 24. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe: author's response.
    Lange C, Kherabi Y, Guglielmetti L, Duarte R, Günther G, Tuberculosis Network European Trials group.
    Clin Microbiol Infect; 2024 Sep; 30(9):1207-1208. PubMed ID: 38901496
    [No Abstract] [Full Text] [Related]

  • 25. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
    Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C, Dodd M, Foraida S, Gegia M, Li M, Mirzayev F, Morgan H, Motta I, Nguyen L, Schumacher S, Schlub T, Fox G.
    Clin Infect Dis; 2024 Mar 20; 78(3):730-741. PubMed ID: 37874021
    [Abstract] [Full Text] [Related]

  • 26. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M, Mok J, Kim DK, Shim TS, Koh WJ, Jeon D, Lee T, Lee SH, Kim JS, Park JS, Lee JY, Kim SY, Lee JH, Jo KW, Jhun BW, Kang YA, Ahn JH, Kim CK, Shin S, Song T, Shin SJ, Kim YR, Ahn H, Hahn S, Won HJ, Jang JY, Cho SN, Yim JJ.
    Trials; 2019 Jan 16; 20(1):57. PubMed ID: 30651149
    [Abstract] [Full Text] [Related]

  • 27. Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK.
    Wolfson LJ, Walker A, Hettle R, Lu X, Kambili C, Murungi A, Knerer G.
    PLoS One; 2015 Jan 16; 10(3):e0120763. PubMed ID: 25794045
    [Abstract] [Full Text] [Related]

  • 28. Cost-effectiveness of bedaquiline or delamanid plus background regimen for multidrug-resistant tuberculosis in a high-income intermediate burden city of China.
    Fan Q, Ming WK, Yip WY, You JHS.
    Int J Infect Dis; 2019 Jan 16; 78():44-49. PubMed ID: 30342251
    [Abstract] [Full Text] [Related]

  • 29. A Bedaquiline, Pyrazinamide, Levofloxacin, Linezolid, and Clofazimine Second-line Regimen for Tuberculosis Displays Similar Early Bactericidal Activity as the Standard Rifampin-Based First-line Regimen.
    Zainabadi K, Vilbrun SC, Mathurin LD, Walsh KF, Pape JW, Fitzgerald DW, Lee MH.
    J Infect Dis; 2024 Aug 16; 230(2):e447-e456. PubMed ID: 38060827
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Impact of adverse drug reactions on the incremental cost-effectiveness of bedaquiline for drug-resistant tuberculosis.
    Schnippel K, Firnhaber C, Page-Shipp L, Sinanovic E.
    Int J Tuberc Lung Dis; 2018 Aug 01; 22(8):918-925. PubMed ID: 29991402
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Economic evaluation of shortened, bedaquiline-containing treatment regimens for rifampicin-resistant tuberculosis (STREAM stage 2): a within-trial analysis of a randomised controlled trial.
    Rosu L, Madan JJ, Tomeny EM, Muniyandi M, Nidoi J, Girma M, Vilc V, Bindroo P, Dhandhukiya R, Bayissa AK, Meressa D, Narendran G, Solanki R, Bhatnagar AK, Tudor E, Kirenga B, Meredith SK, Nunn AJ, Bronson G, Rusen ID, Squire SB, Worrall E, STREAM Study Health Economic Evaluation Collaborators.
    Lancet Glob Health; 2023 Feb 01; 11(2):e265-e277. PubMed ID: 36565704
    [Abstract] [Full Text] [Related]

  • 35. Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen.
    Singh S, Gumbo T, Alffenaar JW, Boorgula GD, Shankar P, Thomas TA, Dheda K, Malinga L, Raj P, Aryal S, Srivastava S.
    Int J Antimicrob Agents; 2023 Dec 01; 62(6):106968. PubMed ID: 37726063
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.